Celestra Health Systems Reports Strong Q1 2026 Growth and Strategic Momentum
CELESTRA HEALTH SYSTEMS — AI-powered gait analysis software platform for monitoring and managing neurological diseases • celestrahealth.com
Celestra Health Systems has released its Q1 2026 Quarterly Update, highlighting a period of strong commercial growth, expanding global demand, and continued innovation in neurological gait measurement.
During the first quarter, the company secured over $500,000 in new contracts, reflecting increasing adoption among pharmaceutical firms and research institutions worldwide. This momentum is further supported by a robust and growing sales pipeline, with opportunities ranging from $50,000 to over $500,000. These developments reinforce Celestra Health’s position as the global leader in the measurement of neurological gait.
Notably, the quarter included the launch of a new clinical trial in the United Kingdom, where Celestra Health’s platform was selected for its unique capability to measure walking fatigability in neurological patients — an increasingly important metric in clinical research. In addition to pharmaceutical applications, the company is also seeing rising demand for data-driven evaluation of rehabilitation interventions, broadening the use cases for its technology.
Celestra Health’s ongoing 12-month Parkinson’s disease clinical trial at The Ottawa Hospital continues to demonstrate exceptional performance. At the nine-month mark, the study has achieved a 100% patient adherence rate, underscoring both the usability of the platform and the engagement of participants.
Research and development remained a central focus throughout the quarter. The company continues to advance its strategy of establishing its platform as both a primary endpoint in neurological drug trials and a standard-of-care clinical measure in neurology practices globally. Its device-agnostic approach — enabling the processing of raw sensor data from a wide range of third-party devices — remains a key differentiator. Enhancements are ongoing to expand measurement capabilities across all aspects of human gait, including walking, turning, standing, and stair navigation.
Looking ahead, Celestra is preparing to launch its first external funding round, with a target close date of July 2026. The company will also participate in the American Academy of Neurology (AAN) 2026 conference in Chicago, where two of its research papers have been accepted for publication, further elevating its scientific profile.
Additional initiatives include a multi-phase user experience enhancement program, informed by research conducted with Carleton University, and continued investment in cybersecurity and data privacy practices as the company works toward SOC 2 certification.
Together, these efforts position Celestra Health Systems for continued growth and industry leadership in 2026.
During the first quarter, the company secured over $500,000 in new contracts, reflecting increasing adoption among pharmaceutical firms and research institutions worldwide.
